Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

baxter holding b.v. - fluconazole - solution for infusion - 2 milligram(s)/millilitre - triazole derivatives; fluconazole

Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

baxter holding b.v. - fluconazole - solution for infusion - 2 milligram(s)/millilitre - triazole derivatives; fluconazole

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

a-s medication solutions - triazolam (unii: 1hm943223r) (triazolam - unii:1hm943223r) - triazolam is indicated for the short-term treatment of insomnia (generally 7 to 10 days) in adults. triazolam is contraindicated in: - patients with known hypersensitivity to triazolam, any of component of triazolam tablets, or other benzodiazepines. reactions consistent with angioedema (involving the tongue, glottis, or larynx), dyspnea, and throat closing have been reported and may be fatal. - concomitant administration of strong cytochrome p450 (cyp 3a) enzyme inhibitors (e.g., ketoconazole, itraconazole, nefazodone, lopinavir, ritonavir) [ see warnings and precautions (5.8), drug interactions (7.1) ] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to triazolam during pregnancy. healthcare providers are encouraged to register patients by calling the national pregnancy registry for other psychiatric medications at 1-866-961-2388 or visiting online at https://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/othermed

Malta - Inggeris - Malta Medicines Authority

vocate pharmaceuticals s.a 150, gounari str, 166 74 glyfada, athens, greece - voriconazole - powder for solution for infusion - voriconazole 200 mg - antimycotics for systemic use

Israel - Inggeris - Ministry of Health

merck sharp & dohme israel ltd - posaconazole - concentrate for solution for infusion - posaconazole 300 mg/vial - posaconazole - noxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adults :- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.- zygomycosis, in patients intolerant of, or with disease that is refractory to, alternative therapy.refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.noxafil concentrate f

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

greenstone llc - triazolam (unii: 1hm943223r) (triazolam - unii:1hm943223r) - triazolam 0.125 mg - triazolam is indicated for the short-term treatment of insomnia (generally 7 to 10 days) in adults. triazolam is contraindicated in: pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to psychiatric medications, including triazolam, during pregnancy. healthcare providers are encouraged to register patients by calling the national pregnancy registry for psychiatric medications at 1-866-961-2388 or visiting online at https://womensmentalhealth.org/pregnancyregistry/. risk summary neonates born to mothers using benzodiazepines late in pregnancy have been reported to experience symptoms of sedation and/or neonatal withdrawal [see warnings and precautions (5.10) and clinical considerations] . available data from published observational studies of pregnant women exposed to benzodiazepines do not report a clear association with benzodiazepines and major birth defects (see data ). the background risk of major birth defects and miscarriage for the indic

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - triazolam (unii: 1hm943223r) (triazolam - unii:1hm943223r) - triazolam 0.25 mg - triazolam is indicated for the short-term treatment of insomnia (generally 7 to 10 days) in adults. triazolam is contraindicated in: - patients with known hypersensitivity to triazolam, any of component of triazolam, or other benzodiazepines. reactions consistent with angioedema (involving the tongue, glottis, or larynx), dyspnea, and throat closing have been reported and may be fatal. - concomitant administration of strong cytochrome p450 (cyp 3a) enzyme inhibitors (e.g., ketoconazole, itraconazole, nefazodone, lopinavir, ritonavir) [see warnings and precautions (5.8), drug interactions (7.1)]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to triazolam during pregnancy. healthcare providers are encouraged to register patients by calling the national pregnancy registry for other psychiatric medications at 1-866-961-2388 or visiting online at https://womensmentalhealth.org/clinical-and-

Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

pharma regulatory solutions ltd - voriconazole - pdr for soln for infusion - 200 milligram - triazole derivatives - antimycotics for systemic use, triazole derivatives - voriconazole is a broad-spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows: treatment of invasive aspergillosis. treatment of candidaemia in non-neutropenic patients. treatment of fluconazole-resistant serious invasive candida infections (including c. krusei). treatment of serious fungal infections caused by scedosporium spp. and fusarium spp. voriconazole should be administered primarily to patients with progressive, possibly life-threatening infections. prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (hsct) recipients.

Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

xellia pharmaceuticals aps - voriconazole - powder for solution for infusion - 200 milligram(s) - triazole derivatives; voriconazole

Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

rowex ltd - voriconazole - powder for solution for infusion - 200 milligram(s) - triazole derivatives; voriconazole